Boehringer Ingelheim
Boehringer Ingelheim, a leading global pharmaceutical company, is headquartered in Ingelheim am Rhein, Germany. Founded in 1885, the company has established a strong presence in the healthcare industry, focusing on human pharmaceuticals, animal health, and biopharmaceutical contract manufacturing. With a commitment to innovation, Boehringer Ingelheim is renowned for its core products, including treatments for respiratory diseases, cardiovascular conditions, and diabetes management. The company’s dedication to research and development has led to significant milestones, positioning it among the top pharmaceutical firms worldwide. Notable achievements include a robust pipeline of novel therapies and a strong market presence in Europe, North America, and Asia. Boehringer Ingelheim continues to enhance its reputation through its unique approach to healthcare solutions, prioritising patient needs and sustainable practices.
DitchCarbon Score
How does Boehringer Ingelheim's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Boehringer Ingelheim's score of 32 is higher than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Boehringer Ingelheim's reported carbon emissions
In 2023, Boehringer Ingelheim reported significant carbon emissions, totalling approximately 295,000,000 kg CO2e for Scope 1 and about 66,000,000 kg CO2e for Scope 2. The company has set ambitious targets to reduce its greenhouse gas emissions, committing to a 58.9% reduction in absolute Scope 1 and 2 emissions by 2030, using 2019 as the baseline year. Additionally, Boehringer Ingelheim aims for a 27.5% reduction in absolute Scope 3 emissions, which encompass emissions from purchased goods and services, capital goods, and other related activities, within the same timeframe. Historically, the company has shown a commitment to reducing its carbon footprint, with emissions from Scope 1 and 2 recorded at approximately 2,666,000 kg CO2e and 2,158,000 kg CO2e in 2015. This reflects a proactive approach to sustainability within the pharmaceutical sector, aligning with industry standards for climate action. The targets set by Boehringer Ingelheim are consistent with the reductions necessary to limit global warming to 1.5°C, demonstrating their commitment to environmental responsibility and climate change mitigation.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 289,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 273,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 3,801,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Boehringer Ingelheim is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
